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incidence
Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58%
of lymphoma series. The crude incidence in the European
Union is 3–4/100 000/year. The incidence increases with age
from 0.3/100 000/year (35–39 years) to 26.6/100 000/year (80–
84 years) [1].
diagnosis
Diagnosis should be made on the basis of a surgical specimen/
excisional lymph node or extranodal tissue biopsy providing
enough material for formalin-ﬁxed samples. Core biopsies may
be appropriate as the only diagnostic test in the rare patients
requiring emergency treatment. Minimal
immunohistochemistry (CD45, CD20, and CD3) is mandatory.
The collection of fresh frozen material for molecular
characterization is recommended although gene expression
proﬁling remains investigational. To ensure adequate quality,
processing by an experienced pathology institute has to be
guaranteed. The histological report should give the diagnosis
according to the current World Health Organization
classiﬁcation [2].
The distinction between germinal center-like subtype and
activated B-cell-like subtype, studied by gene expression
proﬁling and suggested by immunohistochemistry, do not
inﬂuence treatment choices at the moment [3].
staging and risk assessment
A complete blood count, routine blood chemistry including
lactate dehydrogenase (LDH) and uric acid as well as a
screening test for human immunodeﬁciency virus and hepatitis
B and C are required. Protein electrophoresis is recommended.
Patients amenable to curative therapy should have at least a
computed tomography (CT) scan of the chest and abdomen, as
well as a bone marrow aspirate and biopsy. A diagnostic spinal
tap should be considered in high-risk patients [V, D].
[18F]deoxyglucose positron emission tomography (PET)
scanning is strongly recommended to better delineate the
extent of the disease and in view to the evaluation of treatment
response according to the revised criteria [4].
Performance status and cardiac function (left ventricular
ejection fraction) should be assessed before treatment.
The staging is established according to the Ann Arbor
system [I, A] (Table 1). For prognostic purposes, International
Prognostic Index (IPI) and age-adjusted IPI (aa-IPI) should be
calculated [I, A] [5].
treatment
Treatment strategies should be stratiﬁed according to age, age-
adjusted IPI and feasibility of dose-intensiﬁed approaches
(Table 2). Whenever available, the inclusion in a clinical trial
should be considered.
In cases with high tumor load, precautions, as example by
administering prednisone 100 mg p.o. several days as
‘prephase’ treatment, are required to avoid tumor lysis
syndrome. Dose reductions due to hematological toxicity
should be avoided. Febrile neutropenia justiﬁes prophylactic
use of hematopoietic growth factors in patients treated with
curative intent and in all elderly patients.
young low-risk patients (aaIPI = 0) without bulky
disease
Six cycles of combination chemotherapy with cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) treatment
combined with six doses of rituximab given every 21 days is the
current standard [I, A] [6]. Consolidation by radiotherapy to
initial sites has proven no clear beneﬁt [I, A] [7].
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young low-intermediate-risk patients (aaIPI = 1) or
IPI low risk (aaIPI = 0) with bulky disease
R-CHOP 21 × 6 with radiotherapy to the sites of previous
bulky disease was shown to be effective in this group of
patients based on the results of the MINT study [6].
Alternatively, an intensiﬁcation of chemotherapy with R-
ACVBP (rituximab, doxorubicin, vindesine,
cyclophosphamide, bleomycin, and prednisolone given every 2
weeks followed by sequential consolidation) has been shown to
improve survival when compared with eight cycles of R-CHOP
in this category, but in this trial, radiotherapy was omitted in
both arms [I, A] [8]. In this group of patients either R-
CHOP21 × 6 with radiotherapy to the sites of previous bulky
disease or the intensiﬁed regimen R-ACVBP are recommended
[II, B] [8, 9].
young high and high-intermediate-risk patients
(aaIPI≥ 2)
There is no current standard in this subgroup. Thus, especially
this patient population should be treated preferably in clinical
trials. Six to eight cycles of chemotherapy with CHOP
combined with eight doses of rituximab given every 21 days
are most frequently applied [III, B]. Dose-dense treatment with
R-CHOP given every 14 days has not demonstrated survival
Table 2. Recommended treatment strategies in diffuse large B-cell lymphoma
Young <61 years
IPI low risk no bulk IPI low risk with bulk or
IPI low-intermediate risk
IPI intermediate-high risk or IPI high risk
R-CHOP21 × 6 R-ACVBP and sequential
consolidation
Or
R-CHOP21 × 6 + IF-RT on
bulk
R-CHOP21 × 8 or R-CHOP14 × 6 with 8 R
Consider more intensive regimens:
R-CHOEP14 × 6
or
R-ACVBP plus HDCT with ASCT
or
R-dose-dense (R-CHOP14 like) plus R-HDCT
with ASCT
Consider CNS prophylaxis in patients at risk for CNS progression
Elderly >60 years
Healthy >80 years without cardiac
dysfunction
UNFIT or FRAIL or >60 years with cardiac
dysfunction
R-CHOP21 × 8
(R-CHOP21 × 6 for IPI low risk)
or
R-CHOP14 × 6 with 8 R
attenuated regimens:
R-miniCHOP21 × 6
Doxorubicine substitution with etoposide or
liposomal doxorubicine or others:
R-C(X)OP21 × 6
or
palliative care
Consider CNS prophylaxis in patients at risk
First relapse/progress
Eligible to transplant Not eligible to transplant
Platinum-based chemotherapy regimens (i.e. R-DHAP, R-ICE) as salvage
treatment
For chemosensitive patients: R-HDCT with ASCT as remission
consolidation
Consider allogeneic transplantation in patients relapsed after R-HDCT
with ASCT or in patients with poor risk factors at relapse
Platinum and/or gemcitabine-based regimens
Clinical trials with novel drugs
>2 relapse/progress
Eligible to transplant Not eligible to transplant
Allogeneic transplantation
Clinical trials with novel drugs
Clinical trials with novel drugs
Palliative care
Table 1. Ann Arbor staging classiﬁcation
Stage
I Involvement of a single lymphatic region (I) or localized involvement
of single extralymphatic organ or site (IE)
II Involvement of two or more lymphatic regions on the same side of
the diaphragm (II) or localized involvement of a single
extralymphatic organ or site and of one or more lymphatic regions
on the same side of the diaphragm (IIE)
III Involvement of lymphatic regions on both side of the diaphragm.
IV Diffuse or disseminated involvement of one or more extralymphatic
organs with or without lymphatic involvement.
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advantage over standard R-CHOP given every 21 days [I, C]
overall [10]. Moreover, in this trial, R-CHOP 14 failed to show
a better outcome in each DLBCL subset, including young poor
risk. The trial was however not powered enough to compare
different clinical subgroups [10]. Intensive treatment with R-
ACVBP or R-CHOEP is frequently used but these regimens
have not been directly compared with R-CHOP in this
category [II, B]. In the rituximab era, high-dose chemotherapy
(HDC) with stem cell transplantation as consolidation
treatment after immunochemotherapy has shown promising
results in recent phase II trials [II, C] [11–13]. Recently, four
randomized trials comparing R-HDC + ASCT versus R
chemotherapy have been presented. Two trials show a PFS
beneﬁt for HDC with ASCT but no impact, at present, on
survival [14, 15], while two trials failed to demonstrate an
improvement for the HDC arm [16, 17]. Therefore, HDC with
ASCT in ﬁrst line remains experimental in ﬁrst-line therapy or
may be suggested for selective high-risk patients [II, C].
Consolidation by radiotherapy to sites of bulky disease has
proven no beneﬁt [III, C]. The role of radiotherapy in partial
remission remains to be established in patients treated with
rituximab and evaluated with PET [18].
patients aged 60–80 years
Eight cycles of combination chemotherapy with CHOP
treatment combined with eight doses of rituximab given every
21 days is the current standard [I, A] [19]. R-CHOP given
every 14 days did not demonstrate survival advantage over R-
CHOP 21 [I, C] [10, 20]. If rituximab-CHOP is given every 14
days, six cycles of CHOP with eight cycles of rituximab are
sufﬁcient [21]. In patients with localized disease, consolidation
by radiotherapy has proven no beneﬁt [I, A] [22] in patients
treated prior the introduction of rituximab.
patients aged >80 years
A comprehensive geriatric assessment is recommended to help
determine choice of treatment in these patients. R-CHOP
treatment could usually be used until 80 years of age in healthy
patients. The combination of rituximab with attenuated
chemotherapy, as R-miniCHOP, could induce complete
remission and long survival in healthy patients older than 80
years [III, B] [23]. The doxorubicin substitution with etoposide
or liposomal doxorubicin or even its omission can be
considered from the beginning or after a few cycles in patients
with cardiac dysfunction or otherwise unﬁt [IV, C].
CNS prophylaxis
Patients with high-intermediate and high-risk IPI, especially
those with more than one extranodal site or elevated LDH are
at higher risk of central nervous system (CNS) relapse [24].
CNS prophylaxis should be recommended in this population
but intrathecal injections of methotrexate are probably not an
optimal method. Intravenous high-dose methotrexate
associated with efﬁcient disease control could be an interesting
alternative [IV, C] [25, 26]. Whether some speciﬁc involvement
sites as paranasal sinus, upper neck or bone marrow should
receive prophylaxis remains to be established [27]. Testicular
lymphoma must receive CNS prophylaxis.
some extranodal DLBCL require special
consideration
Treatment of primary DLBCL of the central nervous system
must contain high-dose methotrexate. Addition of high-dose
cytarabine seems to improve complete remission rate and
outcome [28]. CNS irradiation is usually administered as
consolidation.
Primary DLBCL of the testis (PTL) is characterized by an
increased risk of extranodal, CNS, and contralateral testis
recurrence with poor outcome [29]. The standard treatment of
localized (stage I to II) PTL is R-CHOP21 with CNS
prophylaxis and contralateral testis irradiation [III, A] [30]. An
open issue remains the type of CNS prophylaxis either with
intrathecal chemotherapy or with the addition of intravenous
high-dose methotrexate or both.
Primary mediastinal large B-cell lymphoma is probably a
distinct entity. R-CHOP 21 is not established as the deﬁnitive
treatment option and radiotherapy remains controversial [31].
response evaluation
Abnormal radiological tests at baseline should be repeated after
three to four cycles and after the last cycle of treatment. Bone
marrow aspirate and biopsy should be only repeated at the end
of treatment if initially involved [4].
PET is highly recommended for the post-treatment
assessment to deﬁne complete remission according to the
revised criteria of response [4]. In case of therapeutic
consequences, a histological conﬁrmation of PET positivity at
this time is strongly recommended. Early PET, performed after
one to four cycles of treatment, have been shown to be
predictive of clinical outcome in some studies, but others did
not ﬁnd any correlations and its results should not lead to
treatment change outside of a clinical trial.
follow-up
History and physical examination every 3 months for 1 year,
every 6 months for 2 more years, and then once a year with
attention to development of secondary tumors or other long-
term side-effects of chemotherapy [V, D].
Blood count and LDH at 3, 6, 12, and 24 months, then only
as needed for evaluation of suspicious symptoms or clinical
ﬁndings in those patients suitable for further therapy [V, C].
Minimal adequate radiological examinations at 6, 12, and 24
months after end of treatment by CT scan are usual practice,
but there is no deﬁnitive evidence that routine imaging in
patients in complete remission provides any outcome
advantage [27, 32]. Routine surveillance with PET scan is not
recommended. High-risk patients with curative options may
potentially mandate more frequent controls.
relapsed and refractory DLBCL
incidence
Overall, >30% of DLBCL will ultimately relapse. The incidence
in the European Union is therefore estimated to be around 1/
100 000/year.
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diagnosis
Histological veriﬁcation should be obtained whenever possible,
and is mandatory in relapses >12 months after the initial
diagnosis, especially in order to ensure CD20 positivity. Image-
guided core biopsy may be appropriate in this context.
staging and risk assessment
Patients still amenable to curative therapy should have the
same examinations as at ﬁrst diagnosis.
treatment
The following recommendations apply to patients with
adequate, rituximab-associated anthracycline-containing ﬁrst-
line therapy.
In suitable patients with adequate performance status (no
major organ dysfunction, age <65–70 years), salvage regimen
with association of rituximab and chemotherapy followed in
responsive patients by high-dose treatment with stem-cell
support is recommended [II, A] [33, 34]. Salvage regimens
such as R-DHAP (rituximab, cisplatin, cytosine arabinoside,
and dexamethasone) or R-ICE (rituximab, ifosfamide,
carboplatin, and etoposide) did not exhibit different outcome
[35]. The possible advantage of R-DHAP in the germinal
center B-cell-like subtype must be conﬁrmed [36]. BEAM
(carmustine, etoposide, cytosine-arabinoside, and melphalan)
is the more frequently used high-dose regimen. Additional
involved-ﬁeld radiation or iceberg radiation may be used
especially in the few cases with limited stage disease, but it has
been never evaluated in controlled trials. Maintenance with
rituximab in responding patients is not recommended [I, D]
[37]. Allogeneic transplantation following chemotherapy
should probably be considered in patients with refractory
disease, early relapse or relapse after ASCT [III, B] [38].
Patients not suitable for high-dose therapy may be treated
with the same or other salvage regimens as R-GEMOX
(rituximab, gemcitabine, and oxaliplatin), which may be
combined with involved-ﬁeld radiotherapy [39] or
preferentially be enrolled in clinical trials testing the activity of
novel drugs.
response evaluation
Response criteria are identical to those of ﬁrst-line treatment
evaluation [4]. An evaluation should be performed after three
to four cycles of salvage regimen (before high-dose treatment)
and after the end of all therapy. The results of PET before
high-dose treatment are correlated to clinical outcome.
follow-up
Follow-up of patients in second response could be the same as
ﬁrst response.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justiﬁed standard clinical practice by the experts and the
ESMO faculty.
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